Evaluation of efficacy and safety of the glucagon receptor antagonist LY2409021 in patients with type 2 diabetes: 12- and 24-week phase 2 studies. Diabetes care 2016;39:1241-1249

Diabetes Care

Volumn 39, Issue 11, 2016, Pages e199-e200

  Kazda, Christof M ^a   Ding, Ying ^a,e   Kelly, Ronan P ^b   Garhyan, Parag ^a   Shi, Chunxue ^c   Lim, Chay Ngee ^a,f   Fu, Haoda ^a   Watson, David E ^a   Lewin, Andrew J ^d   Landschulz, William H ^a   Deeg, Mark A ^a   Moller, David E ^a   Hardy, Thomas A ^a  

^a ELI LILLY AND COMPANY   (United States)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c SYNEOS HEALTH   (United States)

^d NATIONAL RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^f UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOMEGLIVANT; HEMOGLOBIN A1C; TRIACYLGLYCEROL; BIPHENYL DERIVATIVE; GLUCAGON; GLUCAGON RECEPTOR;

CLINICAL EFFECTIVENESS; DOSE RESPONSE; DRUG SAFETY; HUMAN; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 2 CLINICAL TRIAL (TOPIC); TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; ANTAGONISTS AND INHIBITORS;

BIPHENYL COMPOUNDS; DIABETES MELLITUS, TYPE 2; GLUCAGON; HUMANS; RECEPTORS, GLUCAGON;

EID: 84994338973     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dci16-0030     Document Type: Letter

References (4)

1. Agrawal S, Gupta Y. Comment on Kazda et al. Evaluation of efficacy and safety of the glucagon receptor antagonist LY2409021 in patients with type 2 diabetes: 12-and 24-week phase 2 studies. Diabetes Care 2016;39:1241-1249 (Letter).
2. Diabetes Care 2016;39:e198. DOI: 10.2337/dc16-1340
3. Kazda CM, Ding Y, Kelly RP, et al. Evaluation of efficacy and safety of the glucagon receptor antagonist LY2409021 in patients with type 2 diabetes: 12-and 24-week phase 2 studies. Diabetes Care 2016;39:1241-1249
4. Kelly RP, Garhyan P, Raddad E, et al. Shortterm administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes. Diabetes Obes Metab 2015;17:414-422